Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries

Author:

Isah Ambrose O.1ORCID,Opadeyi Abimbola O.2ORCID,Tumwijukye Henry3,Cobelens Frank3,Smith Diede3,Ndomondo-Sigonda Margareth4,Harmark Linda5,Tanui Paul4,Tiemersma Edine6,Mmbaga Blandina T.7,Mahlangu Gugu8,Ayinbuomwan Stephen A.2,Soulaymani Rachida910,Pandit Jayesh M.11

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics, School of Medicine, College of Medical Sciences, University of Benin/University of Benin Teaching Hospital, Benin City, Edo State PMB 1154, Nigeria

2. Department of Clinical Pharmacology and Therapeutics, University of Benin/University of Benin Teaching Hospital, Benin City, Nigeria

3. Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands

4. African Union Development Agency–New Partnership for Africa’s Development (AUDA-NEPAD), Midrand, Johannesburg, South Africa

5. Netherlands Pharmacovigilance Centre Lareb, Den Bosch, The Netherlands

6. KNCV Tuberculosis Foundation, The Hague, The Netherlands

7. KNCV of the Kilimanjaro Clinical Research Institute, Moshi, Tanzania

8. Medicines Control Authority of Zimbabwe, Harare, Zimbabwe

9. WHO Collaborating Centre for Strengthening Pharmacovigilance Practices, Centre

10. Anti Poison et de Pharmacovigilance du Maroc, Rabat, Morocco

11. PV Expert, Kenya, Association of Pharmaceutical Industries (KAPI), Nairobi, Kenya

Abstract

Background: An important factor hindering the growth of pharmacovigilance (PV) in resource-limited settings is the lack of adequate funds to establish a functional National Pharmacovigilance System. Consequently, the crucial function of monitoring and ensuring the availability of safe medicines in these settings cannot be guaranteed considering the peculiarities of diseases and medicines used. Objectives: The objective of this paper is to provide an overview as to the availability of potential sources of funds, which could be explored to ensure Medicine Safety and to proffer a potential framework likely to ensure sustainable funding of PV in Africa. Methods/processes: The process of developing this framework entailed a review of PV financing in some developed economies, a landscape study of funding of PV in some African countries, an in-depth understanding of the PV system and the organisational structure and nexus between the regulatory agencies and National Pharmacovigilance Centre. Critical points for consideration included the sources of funds, revenue pool, the disbursement of funds, budgeting and expenditure profile and the legal framework. Consultative meetings, webinars and interviews with experts were carried out. Results: The findings showed that most of the PV systems were mainly integrated into the regulatory agencies regarding operational and fiscal governance with few facilities being independent of the regulatory agencies. The main source of funding was from the government with significant donor funding which is ad hoc and non-sustainable. Several potential sources were identified but yet to be exploited. There were no legal provisions for PV financing. A framework likely to ensure sustainable PV financing is suggested to capture all available sources of funding, mine the potential sources providing a sizeable pool of revenue to address its activities and enabling legal framework which will engender autonomy. Furthermore, it will address the nexus between the regulatory agencies and the PV outfits, thus enabling appropriate share of resources and blockage of diversions. Conclusion: In all, addressing the various elements identified in this study and providing the legal provisions which guarantees some degree of autonomy will provide a sustainable mechanism for PV funding in the resource-limited setting of Africa.

Funder

European and Developing Countries Clinical Trials Partnership

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Reference30 articles.

1. WHOʼs International Drug Monitoring – The Formative Years, 1968–1975

2. THALIDOMIDE AND CONGENITAL ABNORMALITIES

3. WHO – UMC. Member countries of the WHO programme for international drug monitoring, https://who-umc.org/about-the-who-programme-for-international-drug-monitoring/member-countries/ (accessed 7 March 2023).

4. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands

5. Pharmacovigilance Activities in 55 Low- and Middle-Income Countries

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3